Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
1. A vaccine adviser has been paid for litigation against Merck's Gardasil vaccine. 2. This raises scrutiny and potential reputational risk for MRK's vaccine business.
FAQ
Why Bearish?
Legal challenges and public scrutiny can negatively affect vaccine sales and investor confidence, similar to past litigations impacting stock prices.
How important is it?
The involvement of a new adviser in litigation against MRK's product could lead to financial repercussions.
Why Short Term?
The immediate publicity could influence stock sentiment; however, long-term impacts depend on outcomes.